Summary Although patients with superficial bladder cancer (Ta, TI) have a generally good prognosis, those patients who develop muscle-invasive tumours or metastatic disease at recurrence do poorly clinically. In the current study 69 patients undergoing complete uansurethral resection for superficial transitonal cell cancer of the bladder were investigated for different clinical and biological characteristics as possible prognostic factors: age, sex, performance of instillation therapy and immunohistochemical determination of mutational inactivation of p53 tumour-suppressor gene (monoclonal antibody PAb 1801) as weUl as immunohistochemical determination of the proliferation rate by staining for PCNA (proliferating ceUl nuclear antigen) (monoclonal antibody PC 10). After a median foHow-up of 45.8 months, 12 of 14 patients (85.7%) with more than 20% of cells positive for p53 had disease progression with muscle-invasive growth compared with only one of 55 patients (1.8%) negative for p53 (P <0.01, x2 test). During univariate analysis histological grade (G, vs G2) (P = 0.0373), positivity for PCNA (>60% of ceUls) (P =0.0033) and positivity for p53 (P <0.001) were significant prognostic factors for disease progression (log-rank test), while during multivariate analysis only positivity for p53 was a significant predictor for relapse of bladder cancer (P = 0.0029) (multivariate Cox regression analysis). The immunohistochemical detection of mutations of the p53 gene has been demonstrated to be a reliable, easily performed and thereby widely available technique for the investigation of fresh-frozen or paraffin-embedded tumour specimens. The results demonstrate the important role of the p53 tumoursuppressor gene protein in the development and for the progression of bladder cancer. If the high prognostic value of p53 mutations in superficial bladder cancer is confirmed in larger prospective trials, more aggressive therapeutic strategies could be discussed for patients with p53 mutations in their tumour specimens.
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Keywords: p53 tumour-suppressor gene; prognostic factors; superficial bladder cancer Approximately 80% of patients with papillary transitional cell carcinoma of the bladder will initially be diagnosed with superficial disease. Following transurethral resection 70-80% of these patients will develop disease recurrence within 6-12 months, and in 20% of them the tumour at relapse will be of a higher pathological grade and at a more advanced tumour stage. Therefore, about 10-20% of patients initially diagnosed with superficial bladder cancer will subsequently develop muscle-invasive or metastatic disease. In comparison with patients with superficial bladder cancer, the prognosis of patients with muscle-invasive tumours or metastatic disease is extremely poor (Pocock et al., 1982; Torti and Lum, 1987) . This has resulted in attempts to identify prognostic factors in patients with superficial bladder cancer in order to distinguish patients with a highly aggressive tumour type from those with a much more indolent course of the disease (Pocock et al., 1982) .
The p53 gene has been identified as a tumour-suppressor gene located on chromosome 17p. The product of the gene is a nuclear phosphoprotein involved in cell cycle regulation arresting cells in the G, phase (Lane and Crawford, 1979; Jenkins et al., 1984; Finlay et al., 1989; Bischoff et al., 1990 For the detection of proliferative activity the tumours were immunohistochemically stained for the proliferation marker PCNA. The immunohistochemical reaction for the proliferation marker PCNA was classified in six groups similarly defined to those described above for p53 staining. As additional factors histological grade, the age and sex of patients and performance or absence of instillation therapy were considered. 
Statistical analysis
Univariate analysis by log-rankc tests demonstrated that tumour progression was independent of age (P = 0.9504), sex (P = 0.9754) and performance of former instillation therapy (P = 0.4968). A significant correlation was found with tumour grade (P = 0.0373) and proliferative activity as indicated by PCNA positivity (P = 0.0033) and p53 positivity (P <0.001).
Multivariate analysis revealed p53 overexpression (P = 0.0029) as the most important single prognostic factor for disease progression wh comp with grade (P = 0.8991), age (P = 0.8863), sex (P = 0.6051) and proliferative activity (P = 0.75).
Chi-squared tests were performed to compare p53 overexpression with instillation therapy (P = 0.4487), which was found to be not significantly correlated to p53 positivity. However, p53 expression was statstically significantly correlated with tumour grade (P = 0.024) and a high proliferative activity (> 60% of cells stained positively for PCNA) (P <0.05). (Gerdes, 1990) . Additionally, immunohistochemical positivity for PCNA has been correlated with the grade and stage of bladder tumours (Lipponen and Eskelinen, 1992a) . In a multivariate analysis in patients with superficial, muscle-invasive and metastatic bladder cancer, the percentage of PCNA-positive nuclei was an independent prognostic factor for survival (P = 0.046) (Lipponen and Eskelinen, 1992b) .
The rapid development of new techniques in moleular genetics of tumour cells has expanded the search for useful prognostic factors in bladder cancer. Malignant transformation involves the activation of oncogenes and the mutational inactivation of tumour-suppressor genes (Harris and Hollstein, 1993) . Recent cytogenetic studies have demonstrated non-random changes in chromosomes 1, 5, 7, 9, 11 and 17 in superficial and locally advanced bladder cancer (Borland et al., 1992) . Altered expression of c-erbB-2 as well as mutational inactivation of the tumour-suppressor gene p53 and the retinoblastoma gene (Rb) have been described (Wright et al., 1991) . In a cohort of 43 patients with locally advanced bladder cancer altered Rb expression was identified as an independent prognostic factor for tumour-free survival rate (Logothetis et al., 1992) . The mutational inactivation of the p53 gene was the first genetic alteration demonstrated to occur in primary invasive bladder tumours (Sidransky et al., 1991) .
Mutation of the p53 gene usually leads to a protein with an altered configuration, often assocated with prolonged half-life and higher intracellular levels compared with the wild-type protein, thereby allowing its immunohistochemical detection (Finlay et al., 1988) . The speificity of the immunohistochemical staining reaction for p53 protein was confirmed by comparison of the results with the detection of mutational inactivation of the p53 gene by DNA sequence analysis (Dalbagni et al., 1993) . Accumulation and immunohistochemical detection of the mutated p53 protein has been described for carcinoma of the breast (Horak et al., 1991; Harris, 1992; Thor et al., 1992) , colorectal carcinoma (Hamilton, 1992; Starzynska et al., 1992) and primary lung cancer (Gazdar, 1992; Quinlan et al., 1992) Unfortunately. p53 overexpression in the current study could not be correlated to smoking history owing to absence of the appropriate data in these patients. Smoking has been demonstrated to increase the frequency of p53 mutations for patients with bladder cancer (Spruck et al.. 1993) and may therefore contribute to the prognosis either as part of the change of p53 or independently.
In our study the value of instillation therapy could not be adequately assessed since only a small number of patients had received this treatment modality. Further studies are necessary to clarify the effect of different agents (BCG,mitomycin) and therapeutic regimens for intravesical instillation on the clinical course of bladder tumours possessing a mutational inactivation of the p53 protein. If our results can be confirmed in larger prospective trials, they may be an argument for more aggressive strategies in patients identified by the p53 inactivation in order to prevent tumour recurrence following TUR. If, for example, instillation therapy has no effect on the clinical course of tumours presenting with an inactivation of the p53 tumour-suppressor gene. perhaps because of the clonal but multifocal origin of bladder cancer (Sidransky et al., 1993) , radical cystectomy might be the only curative treatment option.
Interestingly, in contrast to the findings in superficially growing bladder tumours (TI), the immunohistochemical detection of the p53 oncoprotein has no prognostic value in muscle-invasive bladder cancer (Sarkis et al.. 1993b ). This may indicate that inactivation of p53 may represent a rather early event in the development of bladder cancer.
The immunohistochemical approach for p53 is easy, widely available and accurate as compared with DNA sequence analysis (Dalbagni et al., 1993) , and further prospective studies should be encouraged.
